Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$6.40 USD
-0.03 (-0.47%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.38 -0.02 (-0.31%) 6:20 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Coya Therapeutics, Inc.'s return on equity, or ROE, is -48.89% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that COYA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
COYA 6.40 -0.03(-0.47%)
Will COYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Other News for COYA
Coya Therapeutics (COYA) Maintains Buy Rating with Target Price of $18 | COYA Stock News
Coya Therapeutics (COYA) Research Sheds Light on PD Immune Dysfunction | COYA Stock News
Coya Therapeutics publishes new research study on progression of Parkinson's
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and ...
Sixteen new option listings on July 23rd